AMRX

17.29

0.35% 0.06

Dopo l'orario di chiusura: 17.39 0.10 +0.58%

Amneal Pharmaceuticals Inc (AMRX)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Forum Previsione

Precedente Chiudi:

$17.23

Aprire:

$17.11

Volume 24 ore:

2.41M

Relative Volume:

1.36

Capitalizzazione di mercato:

$5.52B

Reddito:

$3.05B

Utile/perdita netta:

$181.32M

Rapporto P/E:

46.35

EPS:

0.373

Flusso di cassa netto:

$186.11M

1 W Prestazione:

+7.32%

1M Prestazione:

+31.28%

6M Prestazione:

+33.93%

1 anno Prestazione:

+112.67%

Intervallo 1D:

$16.87

$17.43

Intervallo di 1 settimana:

$15.93

$17.86

Portata 52W:

$7.665

$17.86

Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile

Nome

Amneal Pharmaceuticals Inc

Settore

Healthcare (1096)

Industria

Drug Manufacturers - Specialty & Generic (85)

Telefono

908-947-3120

Indirizzo

400 Crossing Boulevard, 3rd Floor, Bridgewater

Dipendente

5,210

Cinguettio

@amnealpharma

Prossima data di guadagno

2026-08-04

Ultimi documenti SEC

AMRX's Discussions on Twitter

Compare AMRX vs TAK, HLN, TEVA, ZTS, UTHR

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
AMRX Amneal Pharmaceuticals Inc	17.29	5.50B	3.05B	181.32M	186.11M	0.373
TAK Takeda Pharmaceutical Co Adr	15.98	50.27B	29.91B	1.30B	3.49B	0.4056
HLN Haleon Plc Adr	9.33	40.72B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	33.31	38.67B	17.53B	1.58B	444.18M	1.3457
ZTS Zoetis Inc	73.25	31.90B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	544.92	23.03B	3.17B	1.29B	1.01B	27.09

Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-04-17	Iniziato	UBS	Buy
2025-12-09	Iniziato	Barclays	Overweight
2025-06-06	Iniziato	Goldman	Buy
2025-02-24	Aggiornamento	JP Morgan	Neutral → Overweight
2024-09-06	Aggiornamento	JP Morgan	Underweight → Neutral
2021-04-07	Ripresa	RBC Capital Mkts	Sector Perform
2021-03-08	Aggiornamento	Goldman	Sell → Buy
2020-12-14	Aggiornamento	Barclays	Equal Weight → Overweight
2020-12-14	Aggiornamento	Guggenheim	Neutral → Buy
2020-07-27	Iniziato	Goldman	Sell
2020-05-12	Aggiornamento	Guggenheim	Sell → Neutral
2019-12-12	Downgrade	Raymond James	Outperform → Mkt Perform
2019-11-12	Downgrade	JP Morgan	Neutral → Underweight
2019-11-07	Downgrade	SVB Leerink	Outperform → Mkt Perform
2019-07-22	Aggiornamento	SVB Leerink	Mkt Perform → Outperform
2019-07-11	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
2019-07-08	Aggiornamento	Piper Jaffray	Neutral → Overweight
2019-06-11	Iniziato	Barclays	Equal Weight
2019-05-21	Aggiornamento	Raymond James	Mkt Perform → Strong Buy
2019-03-20	Iniziato	SunTrust	Buy
2019-03-08	Downgrade	SVB Leerink	Outperform → Mkt Perform
2018-12-14	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2018-10-16	Downgrade	SunTrust	Buy → Hold
2018-08-13	Aggiornamento	RBC Capital Mkts	Sector Perform → Outperform
2018-07-23	Iniziato	Morgan Stanley	Overweight
2018-06-22	Iniziato	B. Riley FBR, Inc.	Buy

Mostra tutto

Amneal Pharmaceuticals Inc Borsa (AMRX) Ultime notizie

06:04 AM

Amneal to Buy Kashiv for $375M Cash + 28.9M Shares (NASDAQ: AMRX) - Stock Titan

06:04 AM

05:05 AM

EMA Recommends Approval of Hopledo for Parkinson's Disease - Intellectia AI

05:05 AM

03:10 AM

Zambon and Amneal Receive Positive CHMP Opinion for Hopledo in Parkinson’s Disease in Europe - Quiver Quantitative

03:10 AM

03:00 AM

EU regulator backs Amneal’s Parkinson’s drug after Phase 3 data - Stock Titan

03:00 AM

01:22 AM

Does Amneal (AMRX) Joining Three Russell 2000 Defensive Indexes Recast Its Risk Profile? - simplywall.st

01:22 AM

Jun 28, 2026

Amneal Pharmaceuticals, Inc.(NasdaqGS:AMRX) added to Russell 2000 Value-Defensive Index - marketscreener.com

Jun 28, 2026

Amneal Pharmaceuticals, Inc.(NasdaqGS:AMRX) added to Russell 2000 Growth-Defensive Index - marketscreener.com

Jun 28, 2026

Jun 27, 2026

Form DEF 14A Amneal Pharmaceuticals Inc Class A For: 26 June - Investing.com UK

Jun 27, 2026

2DT Forecast — Price Target — Prediction for 2027 - TradingView

Jun 27, 2026

Jun 25, 2026

Amneal Pharmaceuticals, Inc. Class A Actuals & Estimates (NASDAQ:AMRX) - TradingView

Jun 25, 2026

AMRX Forecast — Price Target — Prediction for 2027 - TradingView

Jun 25, 2026

Jun 23, 2026

Amneal Pharmaceuticals advances after securing FDA clearance for cancer treatment (AMRX) - MSN

Jun 23, 2026

Amneal Pharmaceuticals stock hits 52-week high at 16.62 USD - Investing.com

Jun 23, 2026

Amneal Pharmaceuticals stock hits 52-week high at 16.62 USD By Investing.com - Investing.com South Africa

Jun 23, 2026

Jun 22, 2026

Rytvela from Amneal Pharmaceuticals Inc.biosimilar for chronic uveitis care - AD HOC NEWS

Jun 22, 2026

Amgen Inc. v. Amneal Pharm. LLC United States Court of Appeals of the Federal Circuit, 2020 945 F.3d 1368, 2020 - Sage Journals

Jun 22, 2026

Jun 21, 2026

Amneal Pharmaceuticals (AMRX) Stock Could Be 6% Below Fair Value After Its Sharp Rally - Sahm

Jun 21, 2026

Jun 18, 2026

Amneal (AMRX) agrees to buy Kashiv for $375M cash plus equity and milestones - Stock Titan

Jun 18, 2026

Jun 17, 2026